Treatment of advanced Hodgkin's disease with combination chemotherapy.
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects; D003609:Dactinomycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008212:Lymphocyte Depletion; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use*; D011344:Procarbazine / Q000008:administration & dosage / Q000627:therapeutic use*; D012075:Remission, Spontaneous; D013921:Thrombocytopenia / Q000139:chemically induced; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D003609:Dactinomycin; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D011241:Prednisone